A phase I study of bexarotene and rosiglitazone in patients with refractory cancers

Keyphrases

• Phase I Study 100%
• Rosiglitazone 100%
• Refractory Cancer 100%
• Bexarotene 100%
• Retinoid X Receptor 50%
• Polysome 50%
• Proliferator-activated Receptor-γ 50%
• Solid Tumors 33%
• Hypertriglyceridemia 33%
• Objective Response 33%
• Disease Progression 16%
• Hematological Malignancies 16%
• Nausea 16%
• Dose-limiting Toxicity 16%
• Malignant Cells 16%
• Synergistic Effect 16%
• Insulin-dependent Diabetes 16%
• Ligand-receptor Binding 16%
• Starting Dose 16%
• Dyspnea 16%
• Heavily Pretreated Patients 16%
• Inflammatory Diseases 16%
• Cutaneous T-cell Lymphoma 16%
• Slow Growth 16%
• Dehydration 16%
• Combination Regimen 16%
• Atorvastatin 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Rosiglitazone 100%
• Bexarotene 100%
• Receptor 66%
• Retinoid X Receptor 50%
• Solid Malignant Neoplasm 33%
• Hypertriglyceridemia 33%
• Hematologic Malignancy 16%
• Nausea 16%
• Disease Exacerbation 16%
• Dyspnea 16%
• Preclinical Study 16%
• Inflammatory Disease 16%
• Atorvastatin 16%
• Cutaneous T Cell Lymphoma 16%